Similar to our observations in the PLC xenograft models, metformin or TBOPP monotherapy provided only modest tumor inhibition, while the combination treatment resulted in strong tumor inhibition in the NRASG12V/shP53-induced mouse HCC model (Fig. 4F). This evidence concerns the gene HSPG2 and hepatocellular carcinoma.